Phase 1Not yet recruiting
The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin
- Sponsor
- Johns Hopkins University (Academic or other)
- Enrollment
- 80 planned
- Conditions
- Psilocybin Intoxication
- Interventions
- 0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 15mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 25mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 0mg Psilocybin Capsule + 0.08% BAC Alcoholic Drink
- Ages
- adults, older adults
- Registry
- NCT07877987
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the subjective and behavioral effects of psilocybin relative to placebo and alcohol.
Primary outcomes
- Driving performance as assessed by standard deviation of lateral position (SDLP)
- Driving performance as assessed by global drive score during the simulated driving task
- Total Clues and Cues exhibited during Standardized Field Sobriety Tests (SFSTs)
- Drug Effect Questionnaire (DEQ) - Feel Drug Effect
History
Primary completion expected
Expected to start
Registered